Download App
Current Complaints | Help Center| Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Glenmark Generics Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Glenmark Generics Share Price

BSE Share Price
Not Listed

Glenmark Generics Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Glenmark Generics Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0
TTM Sales
₹0 Cr.
Book Value per Share
₹10
P/E Ratio
0.00
Industry PE
53.6
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
28.70%
Return on Capital Employed (ROCE)
30.18%
Return on Assets (ROA)
12.84%
Operating Profit Margin
29.1%
Net Profit Margin
17.82%
Gross Profit Margin
26.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
9.82%
Operating Profit Growth (1 Year)
-
6.02%
Net Profit Growth (1 Year)
-
-7.02%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
-
Equity
₹149.6 Cr.
Face Value
₹10
All Time Low / High
- / -

Glenmark Generics . - (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14TTM
ROCE % ⓘ-45.2%-1.6%-1.6%-1.5%53%24.5%4%15.2%25.5%25.2%-

Growth Parameters ⓘ
Sales ⓘ00007818261,0691,2831,7261,8961,896
Sales YoY Gr.-NANANANA5.8%29.4%20%34.6%9.8%-
Adj EPS ⓘ-5.6-0.2-0.2-0.119.21013.81228.92626.2
YoY Gr.-NANANANA-48.2%38.4%-12.6%140%-10.1%-
BVPS (₹) ⓘ12.412.212.29.923.869.972.687112.8138.6139.9
Adj Net
Profit ⓘ		-0-0-0-0.5144149207181436392392
Cash Flow from Ops. ⓘ00-0-35.3-19818748946.9525838-
Debt/CF from Ops. ⓘ000-0.6-2.32.71.72010-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNA19.4%21%9.8%
Adj EPS ⓘNA6.3%23.6%-10.1%
BVPSⓘ30.8%42.2%24%22.9%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14TTM
Return on
Equity % ⓘ		-45.2-1.6-1.6-1.4113.724.319.415.12920.718.8
Op. Profit
Mgn % ⓘ		000031.132.426.822.132.729.1NAN
Net Profit
Mgn % ⓘ		000018.41819.314.125.320.720.7
Debt to
Equity ⓘ		0000.32.60.50.80.70.30-
Working Cap
Days ⓘ		00002124354774553252880
Cash Conv.
Cycle ⓘ		00001542181259932-330

Valuation of Glenmark Generics - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Financials

PARTICULARSMar'08Mar'09Mar'13Mar'14
Sales01,032.612,359.562,898.93
Operating Expenses ⓘ + 0.73751.781,565.222,056.80
Manufacturing Costs058.23145.32171.83
Material Costs0456.87946.451,020.75
Employee Cost 079.09199.88265.33
Other Costs ⓘ 0.73157.59273.57598.89
Operating Profit ⓘ -0.73280.83794.35842.14
Operating Profit Margin (%) -27.2%33.7%29.0%
Other Income ⓘ + 085.063.1819.07
Exceptional Items ⓘ 0-116.9600
Interest ⓘ 0.0474.4281.7296.14
Depreciation ⓘ 029.8645.6790.34
Profit Before Tax ⓘ -0.77144.66670.13674.72
Tax ⓘ -0.2654.71114.68158.24
Profit After Tax -0.5189.94555.45516.48
PAT Margin (%) -8.7%23.5%17.8%
Adjusted EPS (₹)-0.112.036.834.2
Dividend Payout Ratio (%)0%0%9.50%0%
PARTICULARSMar'08Mar'09Mar'13Mar'14

Equity and Liabilities

Shareholders Fund + 72.78157.761,617.041,981.69
Share Capital ⓘ 7575150.86151.07
Reserves ⓘ -2.2382.761,466.181,830.62
Debt +22.30682.31949.71560.33
Long Term Debt22.30682.31825.48335.22
Short Term Debt00124.23225.11
Minority Interest0000
Trade Payables00568.83781.46
Others Liabilities ⓘ 2.011,870.45619.80966.04
Total Liabilities ⓘ 97.092,710.513,755.374,289.52

Fixed Assets

Net Fixed Assets ⓘ +54.451,678.141,697.071,906.15
Gross Block56.551,727.531,826.362,124.34
Accumulated Depreciation2.1149.40129.29218.19
CWIP ⓘ 00238.49115.69
Investments ⓘ 0000
Inventories0354.59498.20629.98
Trade Receivables0.56481.82845.64962.76
Cash Equivalents 4.4217.62273.20434.86
Others Assets ⓘ 37.67178.35202.78240.09
Total Assets ⓘ 97.092,710.513,755.374,289.52
PARTICULARSMar'08Mar'09Mar'13Mar'14
Cash Flow From Operating Activity ⓘ + -34.96-84.98604.17824.48
PBT ⓘ -0.77144.66670.13674.72
Adjustment ⓘ 0.36103.80148.15132.97
Changes in Working Capital ⓘ -34.55-250.34-70.21283.77
Tax Paid ⓘ 0-83.09-72.27-172.93
Cash Flow From Investing Activity ⓘ + -5.48-508.55-158.76-132.75
Capex -5.48-392.53-162.14-139.02
Net Investments 0000
Others ⓘ 0-116.023.396.27
Cash Flow From Financing Activity ⓘ + 40.84606.74-306.77-530.07
Net Proceeds from Shares ⓘ 36.9500.530.22
Net Proceeds from Borrowing ⓘ -16.5536.33228.92-391.28
Interest Paid ⓘ 0-48.31-65.61-80.07
Dividend Paid ⓘ 00-61.240
Others ⓘ 20.43618.72-409.37-58.94
Net Cash Flow ⓘ 0.4013.21138.65161.66
PARTICULARSMar'08Mar'09Mar'13Mar'14
Ratios
ROE (%)-0.778.0362.5928.7
ROCE (%)-0.7646.8544.1430.18
Asset Turnover Ratio00.740.730.72
PAT to CFO Conversion(x)N/A-0.941.091.6
Working Capital Days
Receivable Days085.30102.70113.90
Inventory Days0125.306671
Payable Days00109.70241.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Glenmark Generics Ltd. - (Amalgamated) FAQs

The current trading price of Glenmark Generics on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Glenmark Generics stood at ₹0.00 Cr

The latest P/E ratio of Glenmark Generics as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Glenmark Generics as of 31-Dec-1969 is 0.00.

The 52-week high of Glenmark Generics is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glenmark Generics is ₹1,896 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Glenmark Generics Ltd. - (Amalgamated)

Glenmark Generics was originally incorporated as Glenmark Organics on September 29, 1994. It is a subsidiary company of Glenmark Pharmaceuticals (GPL). The company received the certificate of commencement of business on September 12, 1996. The name was changed to Glenmark Generics on November 29, 2007. Consequential to this, a fresh certificate of incorporation was granted to the company on November 29, 2007.

Glenmark is a generic pharmaceutical company with research and development, marketing and distribution capabilities. It focuses on the development, manufacturing, marketing and distribution of generic finished dosage forms (FDFs) through wholesalers, distributors, retailers and other channels, including hospitals and through open tenders.

The company also develops, manufactures, markets and distributes active pharmaceutical ingredients (APIs) to other pharmaceutical companies. For certain products, the company manufactures the APIs used in its FDFs.

It has five manufacturing facilities in India, two of which have been inspected by the US Food and Drug Administration (USFDA) and the Medicines and Healthcare products Regulatory Agency (UK MHRA), and a new facility in Argentina.

Pursuant to a re-organization of the business, GPL transferred its generics business to the company with effect from April 1, 2008 by entering into a business transfer agreement dated December 24, 2008. Further, the company acquired its subsidiary Glenmark Generic Holdings S A by way of a share purchase agreement entered into between Glenmark Holding S A, Switzerland and Glenmark Generics Finance S A, Switzerland, a wholly-owned subsidiary of the Company.

Subsidiaries of the Company:

1. Glenmark Generics Finance S A, Switzerland

2. Glenmark Generics Holding S A, Switzerland

3. Glenmark Generics (Europe), UK

4. Glenmark Generics Inc, USA

5. Glenmark Generics S A, Argentina.

Products offered:

As of September 18, 2009, the company is authorized to distribute approximately 49 FDF products in the US markets, approximately 66 APIs globally and has around 41 Drug Master Files (DMFs) filed with the USFDA. The company's main FDF products are:

  • Oxcarbazepine (anti-convulsant)
  • Gabapentin (anti-convulsant)
  • Hydroxyzine (sedating antihistamine)
  • Naproxen (non-steroidal anti-inflammatory or NSAID)
  • Pravastatin Sodium (anti-lipemic)

Its main API products are:

  • Topiramate
  • Amiodarone
  • Telmistartan
  •  Esomeprazole Magnesium
  •  Lornoxicam
  •  Linezolid
  •  Perindopril Erbumine.

Key milestones:

  • December 24, 2007:- The company entered into a Business Transfer Agreement with GPL for transfer of the generics business.
  • July 4, 2008:- The Bombay High Court approved the scheme of amalgamation of G M Pharma with the company.
  • 2011 -SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with 'Best Company in an Emerging Markets’ & 'Best Overall Pipeline’ titles, for the year 2011.
  • 2010 -Glenmark was conferred the 'Indian Innovator Pharmaceutical Company of the Year' Award for the year 2010 by Frost and Sullivan.
You have 22 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now